Development of novel therapeutics for multidrug-resistant bacterial pathogens by targeting indel-containing essential proteins

Multidrug-resistant (MDR) bacterial pathogens are ubiquitous in hospitals and community settings. New antibiotics against unexploited targets are urgently needed to better control such infections. The proposed research aims to identify novel, drug targets and therapeutics for antibiotic-resistant nosocomial pathogens, capitalizing on a proprietary indel-targeting approach that takes advantage of structural differences between homologous essential human and pathogen proteins. The nominee will help identify small molecule inhibitors for Indel Therapeutics’ microbial drug discovery programs by using the indel-targeting platform to identify the most potent and selective inhibitors for the development of potential antimicrobials for the treatment of multidrug-resistant pathogens. The participation of the intern in the Company’s drug discovery efforts will accelerate the Company’s milestones and increase its internal resources towards higher priority advanced projects.

Faculty Supervisor:

Fiona Brinkman

Student:

Partner:

Indel Therapeutics

Discipline:

Life Sciences

Sector:

Manufacturing

University:

Simon Fraser University

Program: